Please assess the completion status of the following clinical trial:

Trial Title: Montelukast in the Treatment of Duodenal Eosinophilia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A subject will be eligible for inclusion in this study if all of the following criteria are met:~* Patients with dyspepsia defined as upper abdominal pain or discomfort of at least two months duration.~* Male and female subjects 6 - 17 years of age~* Endoscopic mucosal biopsies revealing at least 20 eosinophils in a high power field on specimens from the duodenum in the absence of other defined duodenal pathology.~* Written informed consent signed by the subject's legal guardian and by the investigator and patient assent.~Exclusion Criteria:~Subjects will not be eligible for inclusion in this study if any of the following criteria apply:~* A subject who has previously been treated with montelukast.~* Treatment with steroids or oral cromolyn in the four weeks prior to endoscopy or during the study.~* Any history, clinical, and/or biochemical evidence of clinically significant renal or liver disease.~* Treatment with any inducers or inhibitors of CYP3A4.~* Intake of grapefruit juice or oral vitamin E supplementation

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).